Study title: A double-blind, randomised, parallel group, placebo controlled multicentre study to evaluate the safety and efficacy of a range of doses of cetirizine (2.5 mg, 5 mg and 10 mg once daily) in 6 to 12-year old children suffering from perennial allergic rhinitis.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases | |||||
| Brands: | |||||
| MAH holders: | |||||
| Assessment: | |||||
| Active substance: CETIRIZINE | |||||
| ATC code: | |||||
| Document link: A174 - Cetirizine - RRCE92H2601.pdf | |||||
| Document date: 2011-11-28 | |||||
| Study number: RRCE92H2601 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |